Digestive System Tumor clinical trials at UCSD
2 in progress, 1 open to eligible people
Showing trials for
Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
open to eligible people ages 18 years and up
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-Pugh B7 or B8 cirrhosis.
La Jolla, California and other locations
TheraSphere With Durvalumab and Tremelimumab for HCC
Sorry, in progress, not accepting new patients
The objective of the ROWAN clinical study is to assess the efficacy of local tumor control in HCC patients who receive TheraSphere followed by durvalumab and tremelimumab.
San Diego, California and other locations
Last updated: